Please provide your email address to receive an email when new articles are posted on . Long-acting injectable paliperidone use was associated with significant improvement in clinical and functional ...
Paliperidone (as palmitate) 1092mg/3.5mL, 1560mg/5mL; ext-rel susp for IM inj. Schizophrenia after adequately treated with Invega Sustenna (1-month paliperidone palmitate ext-rel inj susp) for at ...
The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended approval of the antipsychotic Paliperidone Janssen-Cilag International (Janssen-Cilag ...
Trial is the first to study schizophrenia treatment within the context of many real-world issues faced by patients with schizophrenia TITUSVILLE, N.J., April 15, 2015 /PRNewswire/ -- A study published ...
Paliperidone (as palmitate) 273mg, 410mg, 546mg, 819mg; ext-rel susp for IM inj. Schizophrenia after adequately treated with Invega Sustenna (1-month paliperidone palmitate ext-rel inj susp) for at ...
Paliperidone 3 mg, 6 mg, 9 mg; extended-release tabs. Paliperidone is the major active metabolite of risperidone. Although the mechanism of action of this atypical antipsychotic is unknown, the ...
Invega Hafyera (paliperidone palmitate) is a prescription drug that’s used to treat schizophrenia. It’s given as an injection into your muscle by your doctor or another healthcare professional. Invega ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback